Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13873048 | 0.83 | LMNA (0.55) | HTTLMNASMN1; SMN2PKMALDH1A1 | |
| SCHEMBL10122263 | 0.81 | HTT (0.49) | HTTSMN1; SMN2PKMUSP2CTSS | |
| SCHEMBL13993304 | 0.81 | HTT (0.49) | HTTSMN1; SMN2PKMUSP2CTSS | |
| SCHEMBL28186001 | 0.80 | LMNA (0.60) | HTTLMNASMN1; SMN2ALDH1A1GAA | |
| SCHEMBL2757925 | 0.80 | LMNA (0.60) | HTTLMNASMN1; SMN2CYP2C19ALDH1A1 | |
| SCHEMBL11032606 | 0.80 | HTT (0.51) | HTTSMN1; SMN2PKMUSP2CTSS | |
| SCHEMBL3118731 | 0.78 | LMNA (0.58) | HTTLMNASMN1; SMN2CYP2C19ALDH1A1 | |
| SCHEMBL8909399 | 0.78 | HTT (0.50) | HTTLMNASMN1; SMN2PKMUSP2 | |
| SCHEMBL12788486 | 0.77 | LMNA (0.56) | HTTLMNASMN1; SMN2ALDH1A1GAA | |
| SCHEMBL13887704 | 0.77 | LMNA (0.56) | LMNASMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240026358-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2024-01-25 | — | — | US | disclosed |
| US-20230265103-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME THERAPEUTICS LLC | 2023-08-24 | — | — | US | disclosed |
| US-20230203484-A1 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2023-06-29 | — | — | US | disclosed |
| US-20230203087-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-06-29 | — | — | US | disclosed |
| US-20230131535-A1 | ARYLMETHYLENE AROMATIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC | 2023-04-27 | — | — | US | disclosed |
| US-11135227-B2 | Oxygen linked pyrimidine derivatives | CTI BIOPHARMA CORP. (US) | 2021-10-05 | — | — | US | disclosed |
| US-10828305-B2 | Nitrogenous heterocyclic compound, preparation method, intermediate, composition and use | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2020-11-10 | — | — | US | disclosed |
| US-20200071339-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | CTI BIOPHARMA CORP. (US) | 2020-03-05 | — | — | US | disclosed |
| US-20190314330-A1 | IRE-1ALPHA INHIBITORS | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2019-10-17 | — | — | US | disclosed |
| US-20190091226-A1 | NITROGENOUS HETEROCYCLIC COMPOUND, PREPARATION METHOD, INTERMEDIATE, COMPOSITION AND USE | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2019-03-28 | — | — | US | disclosed |
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | US | disclosed |
| US-7514447-B2 | Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors | IRM LLC (BM) | 2009-04-07 | — | — | US | disclosed |
| US-20090075999-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | S*BIO PTE LTD. (SG) | 2009-03-19 | — | — | US | disclosed |
| US-20080139559-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | IRM LLC, A DELAWARE LIMITED LIABILITY COMAPNY (BM) | 2008-06-12 | — | — | US | disclosed |
| US-7368452-B2 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2008-05-06 | — | — | US | disclosed |
| US-20070213315-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2007-09-13 | — | — | US | disclosed |
| US-20070149538-A1 | Diarylamine-Containing Compounds and Compositions, and their use as Modulators of C-Kit Receptors | IRM LLC (BM) | 2007-06-28 | — | — | US | disclosed |
| US-20070149538-A1 | Diarylamine-Containing Compounds and Compositions, and their use as Modulators of C-Kit Receptors | IRM LLC (BM) | 2007-06-28 | — | — | US | disclosed |
| US-20070060510-A1 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2007-03-15 | — | — | US | disclosed |
| US-7176208-B2 | Prevent reproduction of hepatitis virus | ENANTA PHARMACEUTICALS, INC. (US) | 2007-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213315-A1 | Modulators of muscarinic receptors | CHRM3, CHRM5, CHRM2 | HTT 3195/4885LMNA 4093/4885SMN1; SMN2 3349/4885 |
| US-20230265103-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | PIKFYVE, PIK3CD, PIK3R5 | HTT 1760/4885LMNA 4521/4885SMN1; SMN2 3149/4885 |
| US-20190314330-A1 | IRE-1ALPHA INHIBITORS | ERN1, XBP1, ERN2 | HTT 2370/4885LMNA 2261/4885SMN1; SMN2 952/4885 |
| US-20090075999-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | DPYD, TK2, TK1 | HTT 4102/4885LMNA 2856/4885SMN1; SMN2 2852/4885 |
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | EPHX1, EPHX2, NCEH1 | HTT 4722/4885LMNA 3647/4885SMN1; SMN2 4277/4885 |
| US-20230203087-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | RNGTT, NSUN2, ALKBH1 | HTT 1201/4885LMNA 716/4885SMN1; SMN2 285/4885 |
| US-20190091226-A1 | NITROGENOUS HETEROCYCLIC COMPOUND, PREPARATION METHOD, INTERMEDIATE, COMPOSITION AND USE | ERBB2, EGFR, ERBB4 | HTT 1392/4885LMNA 2686/4885SMN1; SMN2 3422/4885 |
| US-11135227-B2 | Oxygen linked pyrimidine derivatives | DPYD, TK2, TK1 | HTT 4102/4885LMNA 2856/4885SMN1; SMN2 2852/4885 |
| US-20200071339-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | DPYD, TK2, TK1 | HTT 4102/4885LMNA 2856/4885SMN1; SMN2 2852/4885 |
| US-20070060510-A1 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors | PRSS1, SPINT2, HPN | HTT 4021/4885LMNA 2324/4885SMN1; SMN2 3819/4885 |
| US-20230131535-A1 | ARYLMETHYLENE AROMATIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | KCNJ2, KCNA3, KCNK3 | HTT 596/4885LMNA 2214/4885SMN1; SMN2 2000/4885 |
| US-20070149538-A1 | Diarylamine-Containing Compounds and Compositions, and their use as Modulators of C-Kit Receptors | KIT, PRKCH, PRKCE | HTT 3827/4885LMNA 710/4885SMN1; SMN2 4559/4885 |
| US-20080139559-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | KIT, PRKCH, PRKCE | HTT 3827/4885LMNA 710/4885SMN1; SMN2 4559/4885 |
| US-10828305-B2 | Nitrogenous heterocyclic compound, preparation method, intermediate, composition and use | ERBB2, EGFR, ERBB4 | HTT 1392/4885LMNA 2686/4885SMN1; SMN2 3422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.